Sionna Therapeutics, Inc.
SION · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Valuation | |||
| PEG Ratio | -0.59 | -1.34 | 0.00 |
| FCF Yield | -4.79% | -4.06% | -3.44% |
| EV / EBITDA | -15.38 | -21.61 | -25.41 |
| Quality | |||
| ROIC | -39.76% | -112.76% | -52.29% |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.92 | 0.90 |
| Growth | |||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -17.85% | -18.11% | 0.00% |
| Safety | |||
| Net Debt / EBITDA | 0.40 | 0.56 | 1.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 |
| Efficiency | |||
| Inventory Turnover | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 |